Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA shows flexibility on unapproved opioids ban

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration, as it moves ahead with its initiative to ensure that all drugs available on the market meet required standards for safety and efficacy, has temporarily allowed seven companies to continue the marketing and distribution of an unapproved opioid drug1. The drug in question is a high-concentrate morphine sulfate oral solution that is widely used to alleviate pain in terminally ill patients.

You may also be interested in...



Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs

The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.

Global Pharma Industry Regulators Seek Unified Approach To Remote Inspections

Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.

Canada Boosts Postmarket Device Safety With New Reporting Rules

Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel